MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

agree a paediatric investigation plan and grant a deferral and grant a waiver

MHRA-101486-PIP01-24

Scope of the Application

Active Substance(s)

Avalotcagene Ontaparvovec

Condition(s)

Treatment of ornithine transcarbamylase deficiency

Pharmaceutical Form(s)

Concentrate for solution for infusion

Route(s) of Administration

INTRAVENOUS USE

Name / Corporate name of the PIP applicant

Ultragenyx Germany GmbH

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Ultragenyx Germany GmbH submitted to the licensing authority on 18/06/2024 15:02 BST an application for a Paediatric Investigation Plan

The procedure started on 10/09/2024 15:18 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan and grant a deferral and grant a waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101486-PIP01-24

Of 23/10/2024 18:29 BST

On the adopted decision for Avalotcagene Ontaparvovec (MHRA-101486-PIP01-24) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for Avalotcagene Ontaparvovec , Concentrate for solution for infusion , INTRAVENOUS USE .

This decision is addressed to Ultragenyx Germany GmbH, Rahel-Hirsch-Strasse 10, Berlin, GERMANY, 10557

ANNEX I

1. Waiver

1.1 Condition:

Treatment of ornithine transcarbamylase deficiency The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 1 month of age Pharmaceutical form(s): Concentrate for solution for infusion Route(s) of administration: INTRAVENOUS USE Reason for granting waiver: on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of ornithine transcarbamylase deficiency

2.2 Indication(s) targeted by the PIP:

Treatment of ornithine transcarbamylase deficiency

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 1 month to less than 18 years of age

2.4 Pharmaceutical Form(s):

Concentrate for solution for infusion

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of a concentrate for solution for infusion for use in the paediatric population.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	2	Study 4 (DTX301-CL301) Randomised, double-blind, placebo-controlled study to evaluate safety and efficacy of DTX301 in patients from 12 years to less than 18 years of age (and adults) with late- onset ornithine transcarbamylase (OTC) deficiency. Study 5 (DTX301-CL302) Open-label study to determine the activity and confirm the safety of DTX301 in paediatric patients with neonatal-onset and late-onset OTC deficiency from 1 month to less than 12 years of age.
Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/10/2024
Deferral of one or more studies contained in the paediatric investigation plan:	Yes